In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $53.36 in the prior trading day, Akero Therapeutics Inc (NASDAQ: AKRO) closed at $51.41, down -3.65%. In other words, the price has decreased by -$3.65 from its previous closing price. On the day, 1.42 million shares were traded. AKRO stock price reached its highest trading level at $53.8255 during the session, while it also had its lowest trading level at $51.12.
Ratios:
Our goal is to gain a better understanding of AKRO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.80 and its Current Ratio is at 16.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 30, 2025, Upgraded its rating to Buy and sets its target price to $63 from $35 previously.
On January 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $50 to $72.
On November 18, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $65.Citigroup initiated its Buy rating on November 18, 2024, with a $65 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 01 ’25 when PATRICK D LAMY bought 2,000 shares for $53.36 per share.
Cheng Andrew sold 6,620 shares of AKRO for $363,041 on Jun 18 ’25. The President and CEO now owns 549,867 shares after completing the transaction at $54.84 per share. On Jun 18 ’25, another insider, Gangloff Scott A., who serves as the Chief Technology Officer of the company, sold 848 shares for $54.84 each. As a result, the insider received 46,504 and left with 23,452 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 4098281728 and an Enterprise Value of 3603661568.
Stock Price History:
The Beta on a monthly basis for AKRO is -0.15, which has changed by 1.3442771 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $21.02. The 50-Day Moving Average of the stock is 7.88%, while the 200-Day Moving Average is calculated to be 33.35%.
Shares Statistics:
The stock has traded on average 1.69M shares per day over the past 3-months and 1995360 shares per day over the last 10 days, according to various share statistics. A total of 79.67M shares are outstanding, with a floating share count of 71.76M. Insiders hold about 9.99% of the company’s shares, while institutions hold 101.98% stake in the company. Shares short for AKRO as of 1749772800 were 7751439 with a Short Ratio of 4.59, compared to 1747267200 on 6297082. Therefore, it implies a Short% of Shares Outstanding of 7751439 and a Short% of Float of 10.0.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of Akero Therapeutics Inc (AKRO).The consensus estimate for the next quarter is -$0.96, with high estimates of -$0.91 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$3.46 and -$3.94 for the fiscal current year, implying an average EPS of -$3.78. EPS for the following year is -$4.42, with 8.0 analysts recommending between -$4.02 and -$4.91.
